Pharmaceutical maker Neuland Laboratories has once again rewarded investors who stayed the course. Its stock climbed 2.87% to touch ₹18,621, and what makes the move remarkable is that it comes on top of a roaring 800% return over the past five years. Far from running out of steam, the counter keeps sprinting ahead. Backing it are not just retail investors but two of the market's most respected names, Mukul Agrawal and Vijay Kedia. With strong fundamentals and a long history as a multibagger, the market expects the stock to keep delivering handsomely.
The real spark behind this fresh rally lies thousands of miles away in the United States. The US FDA has directly reached out to Indian drug companies to address a severe shortage of critical cancer medicines in America. Washington is preparing to lean on Indian firms known for tight regulatory compliance and dependable manufacturing capacity. That development has lifted sentiment across the entire Indian pharma space among investors and traders alike, and Neuland Laboratories is one of the clear beneficiaries.
How Much Mukul Agrawal and Vijay Kedia Own
According to the latest shareholding data for March 2026, Mukul Agrawal holds 4 lakh equity shares in the company, equal to a 3.12% stake. The firm of well-known investor Vijay Kedia holds 1.30 lakh equity shares, or a 1.01% stake. Beyond these big names, foreign institutional investors (FIIs) own 20.46% of the company, while domestic institutional investors (DIIs) hold 15.84%.
Rewards Across Short and Long Term
Neuland Laboratories has filled investors' pockets over both short and long horizons. The stock has risen 7.94% in the past month and returned 18.02% over six months. Over the last year it has gained 46.97%. The most striking figure is the five-year one, where an 800% multibagger return has multiplied investors' money ninefold.
Robust Financial Health
With a market cap of ₹23,890 crore, the company has become a strong player in the pharma sector, and its financials are just as encouraging. Net profit surged 664.8% in the March quarter. Revenue grew 136.4% on a year-on-year basis. On a quarterly basis, the operating profit margin stands at a sturdy 39.6%, while return on equity (ROE) is 19.4%, a solid signal of earnings for shareholders.
On performance too, the stock has left peers behind, outperforming the Nifty-50 by 54.6% and its broader pharma sector by 41.2%.
Keep an Eye on the Valuation
After such a sharp run-up, the stock's P/E ratio has reached 65.6 and its price-to-book (P/B) ratio 12.7, hinting that the valuation has turned a touch expensive at current levels. For investors with a long-term view, gradually accumulating the stock on any major technical correction may prove the smartest strategy.
(Disclaimer: The information here is based on the stock's performance. Investing in the stock market is subject to market risks, so always consult a certified investment advisor before putting in money. Any potential loss remains the investor's own responsibility.)
